Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataGuofeng Chen, George Lau, Wenhong Zhang et al.|PLoS ONE|2016Cited by 44
Clinical application of artificial liver and blood purification: expert consensus recommendationsYu Chen, Zuo Weize, Tao Han et al.|Hepatology International|2022Cited by 24
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 studyRui Hua, Junqi Niu, Fei Kong et al.|Journal of Viral Hepatitis|2022Cited by 7
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in ChinaRui Hua, Junqi Niu, Fei Kong et al.|Infectious Diseases and Therapy|2023Cited by 6
Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in ChinaRui Hua, Junqi Niu, Fei Kong et al.|Research Square|2023Cited by 1